Clinical Trial Update: A Phase II Clinical Trial to Evaluate HLX208 in Advanced Solid Tumor Patients With BRAF V600 Mutation [Phase 2]

View source ↗

Summary

Phase II clinical trial update for HLX208 in advanced solid tumors with BRAF V600 mutation is ongoing; no results or status disclosed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Solid Tumor

Drugs mentioned

• HLX208

Snippet

Sponsor: Shanghai Henlius Biotech | Conditions: Solid Tumor | Phase 2 | Status: UNKNOWN